The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review


Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Myelofibrosis


High impact information on Myelofibrosis


Chemical compound and disease context of Myelofibrosis


Biological context of Myelofibrosis


Anatomical context of Myelofibrosis


Gene context of Myelofibrosis


Analytical, diagnostic and therapeutic context of Myelofibrosis


  1. Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia. Tefferi, A., Mesa, R.A., Gray, L.A., Steensma, D.P., Camoriano, J.K., Elliott, M.A., Pardanani, A., Ansell, S.M., Call, T.G., Colon-Otero, G., Schroeder, G., Hanson, C.A., Dewald, G.W., Kaufmann, S.H. Blood (2002) [Pubmed]
  2. More on Myb in myelofibrosis: molecular analyses of MYB and EP300 in 55 patients with myeloproliferative disorders. Steensma, D.P., Pardanani, A., Stevenson, W.S., Hoyt, R., Kiu, H., Grigg, A.P., Szer, J., Juneja, S., Hilton, D.J., Alexander, W.S., Roberts, A.W. Blood (2006) [Pubmed]
  3. Autonomous megakaryocyte growth in essential thrombocythemia and idiopathic myelofibrosis is not related to a c-mpl mutation or to an autocrine stimulation by Mpl-L. Taksin, A.L., Couedic, J.P., Dusanter-Fourt, I., Massé, A., Giraudier, S., Katz, A., Wendling, F., Vainchenker, W., Casadevall, N., Debili, N. Blood (1999) [Pubmed]
  4. Stimulation of osteoprotegerin production is responsible for osteosclerosis in mice overexpressing TPO. Chagraoui, H., Tulliez, M., Smayra, T., Komura, E., Giraudier, S., Yun, T., Lassau, N., Vainchenker, W., Wendling, F. Blood (2003) [Pubmed]
  5. V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Campbell, P.J., Griesshammer, M., Döhner, K., Döhner, H., Kusec, R., Hasselbalch, H.C., Larsen, T.S., Pallisgaard, N., Giraudier, S., Le Bousse-Kerdilès, M.C., Desterke, C., Guerton, B., Dupriez, B., Bordessoule, D., Fenaux, P., Kiladjian, J.J., Viallard, J.F., Brière, J., Harrison, C.N., Green, A.R., Reilly, J.T. Blood (2006) [Pubmed]
  6. Stem-cell transplantation for myelofibrosis. Deeg, H.J., Appelbaum, F.R. N. Engl. J. Med. (2001) [Pubmed]
  7. High-dose intravenous methylprednisolone for idiopathic myelofibrosis. Ozsoylu, S. Lancet (1988) [Pubmed]
  8. Clinical evidence for 1,25-dihydroxycholecalciferol action in myelofibrosis. Arlet, P., Nicodeme, R., Adoue, D., Larregain-Fournier, D., Delsol, G., le Tallec, Y. Lancet (1984) [Pubmed]
  9. Myelofibrosis associated with rubidazone. Cheng, D.S., Eyre, H.J. Lancet (1978) [Pubmed]
  10. Aetiocholanolone and prednisolone therapy in patients with severe bone-marrow failure. Besa, E.C., Wolff, S.M., Dale, D.C., Gardner, F.H. Lancet (1977) [Pubmed]
  11. Immune complexes in myeloproliferative disorders. Lewis, C.M., Pegrum, G.D. Lancet (1977) [Pubmed]
  12. Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French-American-British Cooperative Group. Bennett, J.M., Catovsky, D., Daniel, M.T., Flandrin, G., Galton, D.A., Gralnick, H.R., Sultan, C. Ann. Intern. Med. (1985) [Pubmed]
  13. Serious myeloproliferative reactions associated with the use of thalidomide in myelofibrosis with myeloid metaplasia. Tefferi, A., Elliot, M.A. Blood (2000) [Pubmed]
  14. Urinary hydroxyproline excretion in myelofibrosis. Wang, J.C., Aung, M.K., Tobin, M.S. Blood (1980) [Pubmed]
  15. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Steensma, D.P., Dewald, G.W., Lasho, T.L., Powell, H.L., McClure, R.F., Levine, R.L., Gilliland, D.G., Tefferi, A. Blood (2005) [Pubmed]
  16. High levels of circulating CD34 cells, dacrocytes, clonal hematopoiesis, and JAK2 mutation differentiate myelofibrosis with myeloid metaplasia from secondary myelofibrosis associated with pulmonary hypertension. Popat, U., Frost, A., Liu, E., Guan, Y., Durette, A., Reddy, V., Prchal, J.T. Blood (2006) [Pubmed]
  17. Increased and pathologic emperipolesis of neutrophils within megakaryocytes associated with marrow fibrosis in GATA-1(low) mice. Centurione, L., Di Baldassarre, A., Zingariello, M., Bosco, D., Gatta, V., Rana, R.A., Langella, V., Di Virgilio, A., Vannucchi, A.M., Migliaccio, A.R. Blood (2004) [Pubmed]
  18. IL-8 and its CXCR1 and CXCR2 receptors participate in the control of megakaryocytic proliferation, differentiation, and ploidy in myeloid metaplasia with myelofibrosis. Emadi, S., Clay, D., Desterke, C., Guerton, B., Maquarre, E., Charpentier, A., Jasmin, C., Le Bousse-Kerdilès, M.C. Blood (2005) [Pubmed]
  19. NF-kappa B as a central mediator in the induction of TGF-beta in monocytes from patients with idiopathic myelofibrosis: an inflammatory response beyond the realm of homeostasis. Rameshwar, P., Narayanan, R., Qian, J., Denny, T.N., Colon, C., Gascon, P. J. Immunol. (2000) [Pubmed]
  20. Diffuse pulmonary uptake of Indium-111 chloride in idiopathic myelofibrosis. Vieras, F., Boyd, C.M., Mora, P.A. Radiology. (1979) [Pubmed]
  21. Abnormalities of GATA-1 in megakaryocytes from patients with idiopathic myelofibrosis. Vannucchi, A.M., Pancrazzi, A., Guglielmelli, P., Di Lollo, S., Bogani, C., Baroni, G., Bianchi, L., Migliaccio, A.R., Bosi, A., Paoletti, F. Am. J. Pathol. (2005) [Pubmed]
  22. Autoimmune myelofibrosis. A steroid-responsive cause of bone marrow fibrosis associated with systemic lupus erythematosus. Paquette, R.L., Meshkinpour, A., Rosen, P.J. Medicine (Baltimore) (1994) [Pubmed]
  23. Extramedullary hematopoietic ascitic fluid cytology in myelofibrosis. Silverman, J.F. Am. J. Clin. Pathol. (1985) [Pubmed]
  24. Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis. Kröger, N., Zabelina, T., Schieder, H., Panse, J., Ayuk, F., Stute, N., Fehse, N., Waschke, O., Fehse, B., Kvasnicka, H.M., Thiele, J., Zander, A. Br. J. Haematol. (2005) [Pubmed]
  25. A pathobiologic pathway linking thrombopoietin, GATA-1, and TGF-beta1 in the development of myelofibrosis. Vannucchi, A.M., Bianchi, L., Paoletti, F., Pancrazzi, A., Torre, E., Nishikawa, M., Zingariello, M., Di Baldassarre, A., Rana, R.A., Lorenzini, R., Alfani, E., Migliaccio, G., Migliaccio, A.R. Blood (2005) [Pubmed]
  26. Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice. Chagraoui, H., Komura, E., Tulliez, M., Giraudier, S., Vainchenker, W., Wendling, F. Blood (2002) [Pubmed]
  27. Etanercept, a soluble tumor necrosis factor receptor, palliates constitutional symptoms in patients with myelofibrosis with myeloid metaplasia: results of a pilot study. Steensma, D.P., Mesa, R.A., Li, C.Y., Gray, L., Tefferi, A. Blood (2002) [Pubmed]
  28. Dysregulation and overexpression of HMGA2 in myelofibrosis with myeloid metaplasia. Andrieux, J., Demory, J.L., Dupriez, B., Quief, S., Plantier, I., Roumier, C., Bauters, F., Laï, J.L., Kerckaert, J.P. Genes Chromosomes Cancer (2004) [Pubmed]
  29. Development of myelofibrosis in mice genetically impaired for GATA-1 expression (GATA-1(low) mice). Vannucchi, A.M., Bianchi, L., Cellai, C., Paoletti, F., Rana, R.A., Lorenzini, R., Migliaccio, G., Migliaccio, A.R. Blood (2002) [Pubmed]
  30. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Deeg, H.J., Gooley, T.A., Flowers, M.E., Sale, G.E., Slattery, J.T., Anasetti, C., Chauncey, T.R., Doney, K., Georges, G.E., Kiem, H.P., Martin, P.J., Petersdorf, E.W., Radich, J., Sanders, J.E., Sandmaier, B.M., Warren, E.H., Witherspoon, R.P., Storb, R., Appelbaum, F.R. Blood (2003) [Pubmed]
  31. Thalidomid: current role in the treatment of non-plasma cell malignancies. Kumar, S., Witzig, T.E., Rajkumar, S.V. J. Clin. Oncol. (2004) [Pubmed]
  32. Major effects of TPO delivered by a single injection of a recombinant adenovirus on prevention of septicemia and anemia associated with myelosuppression in mice: risk of sustained expression inducing myelofibrosis due to immunosuppression. Abina, M.A., Tulliez, M., Lacout, C., Debili, N., Villeval, J.L., Pflumio, F., Wendling, F., Vainchenker, W., Haddada, H. Gene Ther. (1998) [Pubmed]
  33. 2-Chlorodeoxyadenosine treatment after splenectomy in patients who have myelofibrosis with myeloid metaplasia. Tefferi, A., Silverstein, M.N., Li, C.Y. Br. J. Haematol. (1997) [Pubmed]
WikiGenes - Universities